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Journal of Stroke and CRecently, use of mechanical clot retrievers for acute stroke has gradually spread.
However, 3 recent randomized controlled trials failed to show superiority of endo-
vascular treatment compared to intravenous recombinant tissue plasminogen acti-
vator (IV rt-PA) alone or standard care. On the other hand, a Japanese nationwide
survey demonstrated the efficacy of endovascular treatment in the IV rt-PA failed
and ineligible patients, especially with the proximal artery occlusion such as the in-
ternal carotid artery. Earlier initiation and higher reperfusion of endovascular treat-
ment seemed to be themain reason for the better result in this survey comparedwith
the reported randomized studies. Because next-generation devices such as stent re-
trievers have been shown to provide better effects in terms of clinical outcomes
compared with the Merci retriever, the efficacy of endovascular treatment is ex-
pected to be confirmed again by randomized controlled trials in the near
future. Key Words: Acute stroke—clot retriever—tissue plasminogen activator—
randomized trial.
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Despite the increasinguseof intravenous recombinant tis-
sue plasminogen activator (IV rt-PA), the large number of
patients deemed ineligible for treatment because of time re-
strictions, or in whom treatment is ineffective because of
cerebral large vessel occlusion, is nowbecoming recognized
as problematic. Endovascular treatment has therefore
been performed as rescue therapy in these patients.of Neurosurgery, Hyogo College of Medi-
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erebrovascular Diseases, Vol. 23, No. 5 (May-JThree randomized controlled trials were recently
conducted to evaluate the efficacy of endovascular treat-
ment in acute ischemic stroke,1-3 but failed to show the
superiority of endovascular treatment, a finding now
called as the ‘‘Honolulu shock.’’ This article analyzes the
results of those randomized trials and discusses the
future of treatment for these patients.
Problems with IV rt-PA
One problem with IV rt-PA is the large number of pa-
tients who are ineligible for treatment. Less than 5% of
all patients with acute ischemic stroke are eligible for treat-
ment with IV rt-PA. In the European Cooperative Acute
Stroke Study III randomized trial of patients with a delayed
time window for eligibility, IV rt-PA was effective even at
3-4.5 hours after stroke onset.4 Those results led to a slight
reduction in the number of ineligible patients, but major
improvement of this issue has not yet been achieved.
Another problem is the low efficacy rate in patientswith
cerebral large vessel occlusion. In particular, favorableune), 2014: pp e295-e298 e295
Table 1. Summary of 3 recent randomized controlled trials regarding endovascular treatment for acute stroke
IMS III MR RESCUE SYNTHESIS expansion
Endovascular
treatment IV t-PA only P
Endovascular
treatment
penumbral
Standard care
penumbral P
Endovascular
treatment IV t-PA only P
Number of patients 434 222 34 34 181 181
Favorable outcome* 40.8% 38.7% .25 21.0% 26.0% .48 30.4% 34.8% .37
Mortality 19.1% 21.6% .52 18.0% 21.0% .75 14.4% 9.9% .22
Symptomatic ICH 6.2% 5.9% .83 9.0% 6.0% .24 6% 6% .99
Abbreviations: ICH, intracranial hemorrhage; IMS III, Interventional Management of Stroke III; IV t-PA, intravenous tissue plasminogen
activator; MR RESCUE, Mechanical Retrieval and Recanalization of Stroke Clots Using Embolectomy; SYNTHESIS, Local Versus Systemic
Thrombolysis for Acute Ischemic Stroke.
*Modified Rankin scale 0-2 in IMS III and MR RESCUE; 0-1 in Synthesis expansion.
S. YOSHIMURA ET AL.e296outcome rates of only 10%-20% have been reported with
internal carotid artery occlusion. In all cases, this was
due to a failure to recanalize the occluded vessel,5 repre-
senting a limitation of treatment with IV rt-PA.
Endovascular Treatment
The Merci Retriever was the first thrombus retrieval
device, which is indicated within 8 hours of stroke onset
in patients with large vessel occlusion or in those ineligible
for or inwhom IVrt-PA has proven ineffective. In theMulti
MERCI trial,6 the successful recanalization rate (Thrombol-
ysis In Myocardial Infarction score, 2-3) was 68%, and the
favorable outcome rate (modified Rankin Scale [mRS], 0-2)
after 90 days was 36%. On the other hand, the Penumbra
System, which was subsequently approved, achieves
recanalization by thrombus aspiration. In a prospective
study, the recanalization rate (Thrombolysis In Myocardial
Infarction score, 2-3) was 82%, and the favorable outcome
rate (mRS 0-2) was 25%.7 Favorable computed tomography
findings at baseline and recanalizationwithin 5 hours were
reported as good prognostic factors.8
Results of Randomized Controlled Trials
The results of the 3 randomized controlled trials of
endovascular treatment in acute ischemic stroke were
announced at the 2013 International Stroke Conference
held in Honolulu, Hawaii. These included the Interven-
tional Management of Stroke III (IMS-III) study1 evaluating
the effectiveness of endovascular treatment in addition to IV
rt-PA, theMechanicalRetrieval andRecanalizationofStroke
ClotsUsing Embolectomy (MRRESCUE) study2 evaluating
the effectiveness of endovascular treatment based on imag-
ing diagnosis, and the Local Versus Systemic Thrombolysis
for Acute Ischemic Stroke (SYNTHESIS) Expansion study3
comparing IVrt-PA and endovascular treatment (Table 1).
IMS-III
IMS-III was a multicenter, randomized controlled trial
evaluating the effectiveness of endovascular treatmentin addition to IV rt-PA.1 Patients were assigned in a 2:1
ratio to an additional endovascular treatment group and
IV rt-PA alone group. The primary end point was the
mRS 0-2 rate after 90 days.
The study was expected to enroll 900 patients, but was
stopped early after no additional effectiveness was being
shown in the results from 656 patients. The primary end
point did not differ significantly between groups (addi-
tional endovascular treatment group, 40.8%; rt-PA alone
group, 38.8%; 95% confidence interval [CI], 26.1 to 9.1).
Even in a subgroup analysis comparing mild stroke
(National Institutes of Health Stroke Scale score 8-19)
and severe stroke (score $20), there was still no signifi-
cant difference. Furthermore, no significant differences
were identified in mortality after 90 days (P 5 .52) or
the rate of symptomatic intracranial hemorrhage after
30 hours (P 5 .83).
However, the IMS-III study had the following prob-
lems: (1) large vessel occlusion was not confirmed in
more than half of the enrolled patients; (2) the mean
time from IVrt-PA to endovascular treatment was 127 mi-
nutes (Table 2); and (3) the recanalization rate (Thrombol-
ysis in Cerebral Infarction [TICI] grade, 2B-3, which
means perfusion of half or greater of the vascular distri-
bution of the occluded artery) with endovascular
treatment was low, at only about 40% (Table 2).
Based on these results, endovascular treatment should
of course target large vessel occlusions, and shortening
the time until recanalization and higher rate of recanaliza-
tion are important to achieve higher recanalization rates.MR RESCUE
In the MR RESCUE study, patients treated within
8 hours of stroke onset who had large vessel occlusion
(anterior circulation only) were evaluated by magnetic
resonance imaging perfusion imaging to demonstrate
a penumbra region and randomly assigned to an endo-
vascular treatment group or standard treatment group.2
Outcome was assessed according to the 90-day mRS.
Table 2. Comparison of time to puncture and reperfusion after endovascular treatment in IMS III, MR RESCUE, and
RESCUE-Japan registry
0 IMS III MR RESCUE RESCUE-Japan registry
Onset to puncture 370 minutes 210 minutes
IV t-PA to puncture 127 minutes 70 minutes
Reperfusion: TICI 2B-3* ICA: 38%M1: 44% Total: 27% Total: 53%ICA: 56%M1: 60%
Abbreviations: ICA, internal carotid artery; IMS III, Interventional Management of Stroke III; IV t-PA, intravenous tissue plasminogen acti-
vator; M1, middle cerebral artery M1 portion; MR RESCUE, Mechanical Retrieval and Recanalization of Stroke Clots Using Embolectomy;
SYNTHESIS, Local Versus Systemic Thrombolysis for Acute Ischemic Stroke; TICI, thrombolysis in cerebral infarction.
*TICI 2B, perfusion of half or greater of the vascular distribution of the occluded artery, TICI 3, complete reperfusion.
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was more effective in patients with a larger penumbra
(penumbral pattern).
The results showed no difference in mean 90-day mRS
score, which was 3.9 in both groups. Moreover, endovas-
cular treatment was no more effective even in the group
showing a penumbral pattern. However, this study had
the following limitations: (1) the mean time from stroke
onset to initiation of endovascular treatment was 370 mi-
nutes and (2) the recanalization rate (TICI 2B-3) with
endovascular treatment was only 27% (Table 2).
In this study, large vessel occlusion was confirmed by
magnetic resonance angiography before randomization,
no effectiveness was demonstrated. The reason of failure
seemed to be the long time until initiation of endovascular
treatment and a low recanalization rate.SYNTHESIS Expansion
The SYNTHESIS Expansion study randomized patients
with acute ischemic stroke within 4.5 hours of onset to en-
dovascular treatment or IV rt-PA.3 The primary end point
was defined as mRS 0-1 after 3 months (Table 2).
The results showed no significant difference between
groups in the proportion of patients with a good outcome
of mRS 0-1 (P5 .16). The rate of symptomatic intracranial
hemorrhage was 6% in both groups. Median time from
onset until initiation of treatment was 3.75 hours in the
endovascular treatment group and 2.75 hours in the IV
rt-PA group (P , .001). Endovascular treatment was
thus performed 1 hour later.
The major limitation in the SYNTHESIS study, as in the
IMS-III study, was that large vessel occlusion was not
confirmed before randomized assignment. Therefore,
among the 181 patients in the endovascular treatment
group, 165 actually received treatment. Among these,
109 received intra-arterial rt-PA and 56 underwent
mechanical thrombolysis. In other words, about 10% of
patients did not receive endovascular treatment after ran-
domized assignment, and the modality in two thirds of
those patients who did was intra-arterial rt-PA.
These study results, representing the so-called ‘‘Hono-
lulu shock,’’ were announced at the 2013 International
Stroke Conference. However, all 3 studies had significantflaws in their designs and procedures. By addressing
these faults, new directions for better treatment can
come into view.Rescue-Japan Registry
The Rescue-Japan Registry is the first nationwide, pro-
spective registry of acute cerebral large vessel occlusion in
Japan.9 This study was performed to assess the impact of
endovascular treatment on clinical outcome following
approval of a mechanical clot retriever in Japan. The
study demonstrated that endovascular treatment signifi-
cantly improved clinical outcomes in IV t-PA-failed and
-ineligible patients with proximal artery occlusion such
as internal carotid artery.
In this registry, endovascular treatment was started
much earlier (210 minutes after onset in RESCUE-Japan
versus more than 360 minutes in MR RESCUE), and
the reperfusion rate was higher than those of IMS III
and MR RESCUE (TICI 2b-3: 52.5% in RESCUE-Japan
versus 26% in MR RESCUE) (Table 2). The reason for
the higher rate of reperfusion in the present study might
be due to unlimited use of endovascular devices such as
clot retrievers, intracranial/extracranial stents, balloons,
thrombolytic agents, and their combinations, whereas a
single device was allowed to use in IMS III. Another
possible reason is that, in Japan, mechanical clot retrievers
are allowed to be used by a board physician of the
Japanese Society of NeuroEndovascular Therapy, which
requires 100 or more neuroendovascular experience
and passing the board examination. These differences
should be considered when designing future comparative
studies.New Devices
Currently, the most promising new devices are stent-
like thrombus retrieval devices. Stent retrievers allow
thrombectomy to be performed by pulling back the de-
ployed stent into the guide catheter, whereby the struts
of the stent engage the thrombotic material. The device
is applicable repeatedly and can be used even in small pe-
ripheral vessel branches. In contrast with conventional
stent systems, stent retrievers require no anticoagulation
S. YOSHIMURA ET AL.e298or antiplatelet treatment because the stent is not deployed
permanently.
Themaindevices are the stent retrievers such asSolitaire
(ev3) and the Trevo (Concentric Medical). Multicenter,
prospective, randomized controlled trials comparing Soli-
taire andMerci (SWIFTstudy)10 and comparing Trevo and
Merci (Trevo 2 study)11 have already been conducted, and
superiority to the Merci Retriever has been demonstrated.
Because these new devices achieve higher recanalization
rates than previous devices, and the procedure times are
shorter, this type of treatment is expected to becomemain-
stream in the future.
Conclusions
Three recent randomized controlled studies found no
effectiveness of endovascular treatment in acute ischemic
stroke. However, limitations in the 3 studies included that
large vessel occlusion was not yet confirmed, initiation
of treatment was delayed, and recanalization rates were
low. We believe that with the advent of new devices,
controlled studies with modified protocols will demon-
strate the superior effectiveness of endovascular treat-
ment, thus further advancing the treatment of acute
ischemic stroke.
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